In fibroblastic sarcomas, the total score and the cytoplasm-staining score of HMGB1 were positively correlated with CD68, CD163 and CD33 density, indicating that HMGB1 may act on M2-polarized TAMs and CD33-positive myeloid cells in fibroblastic sarcomas and contribute to disease progression. Here, CD33 is linked to sarcoma.